<p>Fennec Pharmaceuticals Inc.（TSE:FRX - 获取免费报告）在周三的交易中跌破了其 50 日移动平均线。该股票的 50 日移动平均线为 C$11.73，最低交易价为 C$10.60。Fennec Pharmaceuticals 的股票最后交易价为 C$10.60，成交量为 103 股。</p>
<p>获取 <strong>Fennec Pharmaceuticals</strong> 的提醒：</p>
<h2>Fennec Pharmaceuticals 价格表现</h2>
<p>该公司的 50 日移动平均线为 C$11.73，200 日移动平均线也为 C$11.73。公司的流动比率为 7.80，速动比率为 10.17，负债权益比为-620.83。公司的市值为 C$3.6202 亿，市盈率为-40.77，贝塔值为 2.51。</p>
<h2>Fennec Pharmaceuticals 的内部活动</h2>
<p>在其他新闻中，内部人士 Southpoint Capital Advisors Lp 于 10 月 9 日星期四出售了 20,609 股该公司的股票。股票以平均价格 C$12.89 出售，总交易额为 C$265,650.01。交易完成后，内部人士直接持有 4,010,100 股公司的股票，价值 C$51,690,189。此次交易使其持股减少了 0.51%。内部人士在过去三个月内出售了 68,889 股公司股票，价值$900,406。内部人士持有公司 16.20% 的股份。</p>
<h2>关于 Fennec Pharmaceuticals</h2>
<p>（获取免费报告）</p>
<p>Fennec Pharmaceuticals Inc 是一家临床阶段的生物技术公司，主要从事研究和开发活动。该公司正在开发硫代硫酸钠（STS），作为一种防止与铂类化疗相关的听力损失的化疗保护剂。其主要产品候选药物是 PEDMARK，这是一种新型配方的硫代硫酸钠，用于预防顺铂引起的听力损失或儿童的耳毒性。</p>
<h2>精选文章</h2>
<ul>
<li>五只我们更看好的股票，胜过 Fennec Pharmaceuticals</li>
<li>如何从成长投资中获利</li>
<li>市场动量：三只有望大幅突破的股票</li>
<li>什么是澳大利亚证券交易所（ASX）</li>
<li>Casey’s General Stores 将继续上涨的三大理由</li>
<li>投资便士股票需要了解的事项</li>
<li>黄金交叉警报：三只具有重大上涨潜力的股票</li>
</ul>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资$1,000 在 Fennec Pharmaceuticals 吗？</h2>
<p>在考虑 Fennec Pharmaceuticals 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Fennec Pharmaceuticals 并不在名单上。</p>
<p>虽然 Fennec Pharmaceuticals 目前在分析师中被评为持有评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>查看这五只股票</p>

FENC

<p>Fennec Pharmaceuticals（TSE:FRX）的股票跌破了其 50 日移动平均线，最低交易价格为 10.60 加元。该股票的 50 日移动平均线为 11.73 加元。内部人士 Southpoint Capital Advisors 以 12.89 加元的价格出售了 20,609 股。Fennec 是一家临床阶段的生物技术公司，正在开发硫代硫酸钠以预防接受化疗的儿童听力损失。尽管分析师给予该股持有评级，但建议其他股票作为更好的投资选择</p>

<p>Fennec Pharmaceuticals Inc. (TSE:FRX - Get Free Report) crossed below its 50 day moving average during trading on Wednesday . The stock has a 50 day moving average of C$11.73 and traded as low as C$10.60. Fennec Pharmaceuticals shares last traded at C$10.60, with a volume of 103 shares traded.</p>
<div class="lb-trans"><p>Fennec Pharmaceuticals Inc.（TSE:FRX - 获取免费报告）在周三的交易中跌破了其 50 日移动平均线。该股票的 50 日移动平均线为 C$11.73，最低交易价为 C$10.60。Fennec Pharmaceuticals 的股票最后交易价为 C$10.60，成交量为 103 股。</p>
</div><p>Get <strong>Fennec Pharmaceuticals</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Fennec Pharmaceuticals</strong> 的提醒：</p>
</div><h2>Fennec Pharmaceuticals Price Performance</h2>
<div class="lb-trans"><h2>Fennec Pharmaceuticals 价格表现</h2>
</div><p>The firm has a fifty day moving average of C$11.73 and a 200 day moving average of C$11.73. The company has a current ratio of 7.80, a quick ratio of 10.17 and a debt-to-equity ratio of -620.83. The company has a market capitalization of C$362.02 million, a P/E ratio of -40.77 and a beta of 2.51.</p>
<div class="lb-trans"><p>该公司的 50 日移动平均线为 C$11.73，200 日移动平均线也为 C$11.73。公司的流动比率为 7.80，速动比率为 10.17，负债权益比为-620.83。公司的市值为 C$3.6202 亿，市盈率为-40.77，贝塔值为 2.51。</p>
</div><h2>Insider Activity at Fennec Pharmaceuticals</h2>
<div class="lb-trans"><h2>Fennec Pharmaceuticals 的内部活动</h2>
</div><p>In other news, insider Southpoint Capital Advisors Lp sold 20,609 shares of the business's stock in a transaction that occurred on Thursday, October 9th. The shares were sold at an average price of C$12.89, for a total transaction of C$265,650.01. Following the completion of the transaction, the insider directly owned 4,010,100 shares of the company's stock, valued at C$51,690,189. The trade was a 0.51% decrease in their ownership of the stock. Insiders have sold 68,889 shares of company stock valued at $900,406 in the last three months. Insiders own 16.20% of the company's stock.</p>
<div class="lb-trans"><p>在其他新闻中，内部人士 Southpoint Capital Advisors Lp 于 10 月 9 日星期四出售了 20,609 股该公司的股票。股票以平均价格 C$12.89 出售，总交易额为 C$265,650.01。交易完成后，内部人士直接持有 4,010,100 股公司的股票，价值 C$51,690,189。此次交易使其持股减少了 0.51%。内部人士在过去三个月内出售了 68,889 股公司股票，价值$900,406。内部人士持有公司 16.20% 的股份。</p>
</div><h2>About Fennec Pharmaceuticals</h2>
<div class="lb-trans"><h2>关于 Fennec Pharmaceuticals</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Fennec Pharmaceuticals Inc is a clinical-stage biotechnology company. It is primarily engaged in research and development activities. The company is developing Sodium Thiosulfate (STS), a chemo-protectant against hearing loss associated with platinum-based chemotherapy. Its lead product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin induced hearing loss, or ototoxicity in children.</p>
<div class="lb-trans"><p>Fennec Pharmaceuticals Inc 是一家临床阶段的生物技术公司，主要从事研究和开发活动。该公司正在开发硫代硫酸钠（STS），作为一种防止与铂类化疗相关的听力损失的化疗保护剂。其主要产品候选药物是 PEDMARK，这是一种新型配方的硫代硫酸钠，用于预防顺铂引起的听力损失或儿童的耳毒性。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>精选文章</h2>
</div><ul>
<li>Five stocks we like better than Fennec Pharmaceuticals</li>
<li>How to Profit From Growth Investing</li>
<li>Market Momentum: 3 Stocks Poised for Major Breakouts</li>
<li>What is the Australian Securities Exchange (ASX)</li>
<li>3 Reasons Casey’s General Stores Will Continue Trending Higher</li>
<li>What to Know About Investing in Penny Stocks</li>
<li>Golden Cross Alert: 3 Stocks With Major Upside Potential</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，胜过 Fennec Pharmaceuticals</li>
<li>如何从成长投资中获利</li>
<li>市场动量：三只有望大幅突破的股票</li>
<li>什么是澳大利亚证券交易所（ASX）</li>
<li>Casey’s General Stores 将继续上涨的三大理由</li>
<li>投资便士股票需要了解的事项</li>
<li>黄金交叉警报：三只具有重大上涨潜力的股票</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Fennec Pharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资$1,000 在 Fennec Pharmaceuticals 吗？</h2>
</div><p>Before you consider Fennec Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Fennec Pharmaceuticals 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Fennec Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Fennec Pharmaceuticals 并不在名单上。</p>
</div><p>While Fennec Pharmaceuticals currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Fennec Pharmaceuticals 目前在分析师中被评为持有评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五只股票</p>
</div>

Fennec Pharmaceuticals（TSE:FRX）的股价跌破了 50 日移动平均线 - 接下来会发生什么？